{"id":"W2947664767","doi":"10.1200/jco.2019.37.15_suppl.4500","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Clinical endpoint; Internal medicine; Axitinib; Oncology; Everolimus; Urology; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002279872,0.001138487,0.001747501,0.0003939389,0.000328346,0.0008413518,0.0008570179,0.001047202,0.003346569],"category_scores_gemma":[0.001001142,0.0005919963,0.001755968,0.0004718933,0.0005648631,0.0008156116,0.0005639617,0.002181299,0.000663902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052601,"about_ca_system_score_gemma":0.001216018,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001235124,"about_ca_topic_score_gemma":0.004083235,"domain_scores_codex":[0.999365,0.0003545713,0.00003660651,0.00009153011,0.00005474658,0.00009756262],"domain_scores_gemma":[0.9993792,0.00009809572,0.0001837026,0.00003746638,0.00002571834,0.0002757929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9566541,0.009572805,0.00505299,0.0004935702,0.001855077,0.0000574303,0.00007874347,0.0009413352,0.005721235,0.00006908963,0.001107431,0.01839617],"study_design_scores_gemma":[0.6525643,0.3089992,0.0301445,0.00007638035,0.002585091,0.0002254932,0.00007518105,0.001262944,0.001793178,0.0002113782,0.002030735,0.00003167981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942294,0.002121329,0.0001879889,0.0002107875,0.00007834891,0.001039787,0.0009326186,0.00002920142,0.00117048],"genre_scores_gemma":[0.9945897,0.001165684,0.000476656,0.0004083596,0.0001237215,0.0008621129,0.001141977,0.000009292205,0.001222533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003346569,"threshold_uncertainty_score":0.0120573,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1072575345345061,"score_gpt":0.4269286395181067,"score_spread":0.3196711049836006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}